Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy

Abstract Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to surgical intervention. The rationale is that shrinking a tumor will improve surgical outcomes and minimize...

Full description

Bibliographic Details
Main Authors: John ML Ebos, Michalis Mastri, Christina R Lee, Amanda Tracz, John M Hudson, Kristopher Attwood, William R Cruz‐Munoz, Christopher Jedeszko, Peter Burns, Robert S Kerbel
Format: Article
Language:English
Published: Springer Nature 2014-12-01
Series:EMBO Molecular Medicine
Subjects:
antibodies
neoadjuvant
surgery
tyrosine kinase inhibitors
VEGF
Online Access:https://doi.org/10.15252/emmm.201403989

Internet

https://doi.org/10.15252/emmm.201403989

Similar Items